ASCO GU 2026: Updates in localised prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer
Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up
ESMO 2025: Latest developments in endometrial cancer
ESMO 2025: Highlights and analysis
Best practice in precision medicine for prostate cancer
ESMO 2025: Prostate highlights
177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity
Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors
ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC